
|Videos|November 4, 2015
How Have High Cost Hepatitis C Drugs Impacted Specialty Pharmacy?
Author(s)Davy James, Managing Editor
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Advertisement
Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5


























